GlassScriptPhysician profile
Thomas H Phillips
NPI 1801839378
$3,465.39
in general payments reported to CMS, 2019-2025
35 companies · $41.26 in 2025
The $41.26 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $509 · 2021: $798 · 2022: $96.13 · 2023: $275 · 2024: $148 · 2025: $41.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $770.32 | 2019-2021 | |
| Coloplast Corp | $521.04 | 2019-2024 | Speedicath |
| Antares Pharma, INC. | $253.51 | 2019-2022 | |
| Procept Biorobotics Corporation | $223.04 | 2019 | |
| Abbvie INC. | $222.29 | 2019-2021 | |
| Neotract INC. | $183.96 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $174.47 | 2019-2023 | Provenge |
| Endo Pharmaceuticals INC. | $137.28 | 2019-2021 | |
| Boston Scientific Corporation | $132.24 | 2019-2021 | |
| Pfizer INC. | $121.33 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $110.62 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $53.42 | 2021 | |
| Abc Home Medical Supply, INC. | $50.39 | 2023-2024 | |
| C. R. Bard, INC. & Subsidiaries | $44.56 | 2019 | |
| Clarus Therapeutics INC. | $38.76 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $38.14 | 2019 | |
| Hollister Incorporated | $31.79 | 2023 | Onli, Infyna Chic, Vapro |
| Convatec INC. | $31.46 | 2023 | |
| Acerus Pharmaceuticals Corporation | $26.25 | 2020-2021 | |
| Smith+Nephew, INC. | $25.44 | 2021 | |
| Therapeuticsmd, INC. | $25.00 | 2019-2020 | |
| Zyla Life Sciences, INC. | $24.59 | 2019 | |
| Janssen Biotech, INC. | $24.24 | 2024 | Erleada |
| Myovant Sciences INC. | $23.88 | 2021 | |
| Photocure INC | $21.11 | 2025 | Cysview |
| Verity Pharmaceuticals INC. | $20.15 | 2025 | Trelstar |
| Baudax Bio INC. | $19.54 | 2020 | |
| Tolmar, INC. | $19.31 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.03 | 2019 | |
| Allergan, INC. | $14.41 | 2021 | |
| Agiliti Health, INC. | $14.37 | 2020 | |
| Metuchen Pharmaceuticals | $14.32 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $13.92 | 2019 | |
| Axogen | $13.20 | 2020 | |
| Dentsply Ih INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.